- Tuesday, December 23, 2025
- India +91 7982732466
- U.S +1 217 953 4020
- Info@Shingetsuresearch.com
Global In-Silico Drug Discovery Market by Workflow (Discovery (Target Identification, Target Validation and Lead Discovery), Pre-Clinical Tests and Clinical Trials), By Product (Software, and Service),By Software Type(Molecular Modeling and de Novo Drug Design Software and Pharmacophore Modeling Software), By End-User(Contract Research Organizations, Pharmaceutical Industry, Academic and Research Institutes and Other (Hospitals and Other Care Facilities)) and By Region (North America, Europe, Asia Pacific, South America, and Middle East & Africa)
Global In-Silico Drug Discovery Market Overview:
Global In-Silico Drug Discovery Market is estimated to reach USD 5.3 billion by 2030, growing at a CAGR of 7.4% during the forecast period of 2022-2030. It was valued at USD 2.8 billion in 2022. In-Silico Drug Discovery or Computer-aided drug discovery (CADD) is a comprehensive platform for new drug research and development that integrates a variety of computer applications. It is mainly used in the early preclinical research of small molecule drug research and development, including the screening of active compounds, optimization of lead compounds, and clinical candidates in different stages of medicine. In recent years, based on the rapid development of information technology and the breakthrough in computational chemistry, more and more new drug compounds have been discovered through the use of rational drug design strategies. With the application of artificial intelligence and cloud computing, it is foreseeable that in-silico drug discovery will play a more significant role in new drug research and development projects, improve research and development efficiency. In-silico drug discovery further reduces high research and development costs.Global In-Silico Drug Discovery Market Insights
The growing emphasis on reduction in medical errors and readmission rates are major factors expected to drive the global in-silico drug discovery market in the future timeframe. Moreover, the growth in the biomarker identification market and advancements in the field of computational biology would propel the growth of the global in-silico drug discovery market size in the forthcoming periods. Additionally, the increasing number of drug discovery projects, coupled with the rapid progression in various stages of drug discovery, will augment the global in-silico drug discovery industry. Furthermore, the main objective of in-silico drug discovery to reduce costs and late-stage attrition likely to spur the growth of in-silico drug discovery. In-silico drug discovery use in drug development helps in selecting only a potent lead molecule and may thus prevent late-stage clinical failures; thereby, a significant reduction in cost can be achieved. The upsurge in demand for in-silico drug discovery in cost-saving, time to market, speed up drug discovery and development, and in-sight knowledge of drug-receptor interactions will lead to the robust growth of the global In-Silico Drug Discovery market share in the estimated period.Growth Driver
The surge in demand for in-silico drug discovery to improve the efficiency of the drug discovery and development pipeline
In-silico drug discovery or CADD is also a vital innovation platform in the research and development of small-molecule new drugs. Compared with traditional drug discovery methods, one of the outstanding advantages of CADD is the quantitative and dynamic analysis of the interaction between small molecule compounds and their biological targets based on their three-dimensional structure, and ligands and receptors through CADD. In-silico drug discovery technology takes only a few minutes to a few hours of direct analysis of the structure of these small-molecule compounds. It further combined with computer-simulated compound drug-like properties and drug metabolism and toxicity (ADMET), directly screen and optimize the designed small molecule compounds. It reduces the number of compounds that need to be synthesized and tested, thus significantly reduce R & D costs and accelerate the efficiency of the new drug.Workflow Segmental Analysis
Based on workflow, the global in-silico drug discovery market classified Discovery (Target Identification, Target Validation, and Lead Discovery), Preclinical Tests, and Clinical Trials. The Discovery segment predicted to gain a significant share in the in-silico drug discovery market by 2030. It is owing to the in-silico drug is used in the early preclinical development of small molecule drugs, including target identification, target validation, and lead discovery. The clinical trials segment will drive on account of in-silico drug discovery help in continue to effective clinical trials.Product Segmental Analysis
Based on product, the global in-silico drug discovery market bifurcated into Software, and Service. The software segment projected to dominate the in-silico drug discovery market by 2030. It is due to software help in identify novel hits or leads against selected therapeutic targets, with the help of 2D similarity searches, 3D pharmacophore searches, and high throughput docking of databases. The services segment will influence a lucrative growth rate during the forecast period; as a result of its help in support of drug discovery projects.Software Type Segmental Analysis
Based on the Software, the global In-Silico Drug Discovery market segregated into Molecular Modeling Drug Design Software and Pharmacophore Modeling Software. The Molecular Modeling Drug Design Software segment witnessed to dominate the market during the estimated period. It is due to the benefits of molecular modeling, such as it examines molecular conformations, molecular motions, and intermolecular interactions such as ligand-receptor complex and perform molecular dynamics at constant temperatures. Pharmacophore Modeling Software will propel throughout the period on account of its help in elucidate key molecular and then exploit it for molecular design.End-User Segmental Analysis
Based on end-user, the global in-silico drug discovery market categorized into Contract Research Organizations, Pharmaceutical Industry, Academic and Research Institutes, and Other (Hospitals and Other Care Facilities. Pharmaceutical Industry segment expected to gain maximum revenue by 2030 owing to the huge demand for in-silico drug discovery in drug development with minimum cost and error-free drug development. The Contract Research Organizations segment in the forecast period will drive due to the support in drug discovery projects of any pharmaceutical, biotechnology, and medical device industries.Region Segmental Analysis
Based on geography, the global in-silico drug discovery market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America estimated to occupy the lion’s share in the in-silico drug discovery market by 2030. It is primarily attributed to the presence of key players in these regions coupled with huge developments of drugs for various diseases. The Asia Pacific will drive with a significant growth rate during the projected period. It is due to rapid growth in the pharmaceutical and biopharmaceutical industry, along with the presence of less-stringent regulations for drug discovery processes.Competitor Analysis
Companies such as Albany Molecular Research Inc., Certara USA, Inc., Charles River, Chemical Computing Group, Collaborative Drug Discovery Inc., Dassault System (Biovia), Evotec A.G., GVK Biosciences Private Limited, ICAGEN, INC. , Novo Informatics Pvt. Ltd., Numerate Inc., PerkinElmer Inc, Schrödinger, LLC, Selvita, Simulation Plus, and WuXi AppTec are the key players in the Global In-Silico Drug Discovery Market.Key Stakeholders
- Market research and consulting firms
- Industry associations
- Global in-silico drug discovery manufacturing firm
- Research organizations and consulting companies
- Organizations, associations, and alliances related to in-silico drug discovery
- Regulatory bodies
- Suppliers
- Retailers
The objective of the Research
- Market modeling starts with identifying a target market where historical data exists. A Market can include prediction problems, economic factors, analyzing customer behavior, and identifying new patterns from past events, which helps our client to have deep dive into the market.
- Product analysis involves steps such as examining product features, costs, availability, quality, and other aspects. Product analysis is conducted to understand potential buyers and measure competition in the market.
- Market Trend and Economic Factors Analysis helps in assessing potential changes to an economy’s inflation rate, taxes, interest rates, exchange rates, trading regulations, and excise duties that can or have a major effect on the target market.
- Market Segmental Analysis defines in-depth scenario of the target market by the process of grouping consumers into naturally existing created segments of consumers who share similar product preferences or characteristics
- The geographical mapping approach helps our clients to understand national or international markets because different consumers in different regions have different needs wants, and cultural characteristics that can be specifically targeted.
Market Modelling
By Workflow- Discovery
- Target Identification
- Target Validation
- Lead Discovery
- Pre-Clinical Tests
- Clinical Trials
- Software
- Service
- Molecular Modeling Drug Design Software
- Pharmacophore Modeling Software
- Contract Research Organizations
- Pharmaceutical Industry
- Academic and Research Institutes
- Other (Hospitals and Other Care Facilities)
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
More Related Reports:
Super Absorbent Polymers Market
Report Content
- Research Strategic Development
1.1. Market Modelling
1.2. Product Analysis
1.3. Market Trend and Economic Factors Analysis
1.4. Market Segmental Analysis
1.5. Geographical Mapping
1.6. Country Wise Segregation
- Research Methodology
2.1. Identification of Target Market
2.2. Data Acquisition
2.3. Refining of Data/ Data Transformations
2.4. Data Validation through Primary Techniques
2.5. Exploratory Data Analysis
2.6. Graphical Techniques/Analysis
2.7. Quantitative Techniques/Analysis
2.8. Visual Result/Presentation
- Executive Summary
- Market Insights
4.1. Supply Chain Analysis
4.2. Economic Factor Analysis
4.2.1. Drivers
4.2.2. Trends
4.2.3. Opportunities
4.2.4. Challenges
4.3. Technological Landscape
4.4. Competitors & Product Analysis
4.5. Regulatory Framework
4.6. Company market share analysis, 2022
4.7. Porter’s Five forces analysis
4.8. Price point analysis
4.9. New Investment Analysis
4.10. PESTEL Analysis
- Global In-Silico Drug Discovery Market Overview
5.1. Market Size & Forecast,2017-2030
5.1.1. Demand
5.1.1.1. By Value (USD Billion)
5.2. Market Share & Forecast, 2017-2030
5.2.1. By Workflow
5.2.1.1. Discovery
5.2.1.1.1. Target Identification
5.2.1.1.2. Target Validation
5.2.1.1.3. Lead Discovery
5.2.1.2. Pre-Clinical Tests
5.2.1.3. Clinical Trials
5.2.2. By Product
5.2.2.1. Software
5.2.2.2. Services
5.2.3. By Software Type
5.2.3.1. Molecular Modeling Drug Design Software
5.2.3.2. Pharmacophore Modeling Software
5.2.4. By End-User
5.2.4.1. Contract Research Organizations
5.2.4.2. Pharmaceutical Industry
5.2.4.3. Academic and Research Institutes
5.2.4.4. Others (Hospitals and Other Care Facilities)
5.2.5. By Region
5.2.5.1. North America
5.2.5.2. Europe
5.2.5.3. Asia-Pacific
5.2.5.4. South America
5.2.5.5. The Middle East & Africa
- North America In-Silico Drug Discovery Market Overview
6.1. North America In-Silico Drug Discovery Market Size & Forecast,2017-2030
6.1.1. Demand
6.1.1.1. By Value (USD Billion)
6.2. Market Share & Forecast, 2017-2030
6.2.1. By Workflow
6.2.1.1. Discovery
6.2.1.1.1. Target Identification
6.2.1.1.2. Target Validation
6.2.1.1.3. Lead Discovery
6.2.1.2. Pre-Clinical Tests
6.2.1.3. Clinical Trials
6.2.2. By Product
6.2.2.1. Software
6.2.2.2. Services
6.2.3. By Software Type
6.2.3.1. Molecular Modeling Drug Design Software
6.2.3.2. Pharmacophore Modeling Software
6.2.4. By End-User
6.2.4.1. Contract Research Organizations
6.2.4.2. Pharmaceutical Industry
6.2.4.3. Academic and Research Institutes
6.2.4.4. Others (Hospitals and Other Care Facilities)
6.2.5. By Country
6.2.5.1. US
6.2.5.2. Canada
6.2.5.3. Mexico
6.2.6. Company Market Share (Top 3-5)
6.2.7. Economic Impact Study on North America In-Silico Drug Discovery Market
- Europe In-Silico Drug Discovery Market Overview
7.1. Europe In-Silico Drug Discovery Market Size & Forecast,2017-2030
7.1.1. Demand
7.1.1.1. By Value (USD Billion)
7.2. Market Share & Forecast, 2017-2030
7.2.1. By Workflow
7.2.1.1. Discovery
7.2.1.1.1. Target Identification
7.2.1.1.2. Target Validation
7.2.1.1.3. Lead Discovery
7.2.1.2. Pre-Clinical Tests
7.2.1.3. Clinical Trials
7.2.2. By Product
7.2.2.1. Software
7.2.2.2. Services
7.2.3. By Software Type
7.2.3.1. Molecular Modeling Drug Design Software
7.2.3.2. Pharmacophore Modeling Software
7.2.4. By End-User
7.2.4.1. Contract Research Organizations
7.2.4.2. Pharmaceutical Industry
7.2.4.3. Academic and Research Institutes
7.2.4.4. Others (Hospitals and Other Care Facilities)
7.2.5. By Country
7.2.5.1. Germany
7.2.5.2. UK
7.2.5.3. France
7.2.5.4. Italy
7.2.5.5. Rest of Europe
7.2.6. Company Market Share (Top 3-5)
7.2.7. Economic Impact Study on Europe In-Silico Drug Discovery Market
- Asia-Pacific In-Silico Drug Discovery Market Overview
8.1. Asia-Pacific In-Silico Drug Discovery Market Size & Forecast,2017-2030
8.1.1. Demand
8.1.1.1. By Value (USD Billion)
8.2. Market Share & Forecast, 2017-2030
8.2.1. By Workflow
8.2.1.1. Discovery
8.2.1.1.1. Target Identification
8.2.1.1.2. Target Validation
8.2.1.1.3. Lead Discovery
8.2.1.2. Pre-Clinical Tests
8.2.1.3. Clinical Trials
8.2.2. By Product
8.2.2.1. Software
8.2.2.2. Services
8.2.3. By Software Type
8.2.3.1. Molecular Modeling Drug Design Software
8.2.3.2. Pharmacophore Modeling Software
8.2.4. By End-User
8.2.4.1. Contract Research Organizations
8.2.4.2. Pharmaceutical Industry
8.2.4.3. Academic and Research Institutes
8.2.4.4. Others (Hospitals and Other Care Facilities)
8.2.5. By Country
8.2.5.1. India
8.2.5.2. Japan
8.2.5.3. Australia
8.2.5.4. Rest of Asia Pacific
8.2.6. Company Market Share (Top 3-5)
8.2.7. Economic Impact Study on Asia Pacific In-Silico Drug Discovery Market
- South America In-Silico Drug Discovery Market Overview
9.1. South America In-Silico Drug Discovery Market Size & Forecast,2017-2030
9.1.1. Demand
9.1.1.1. By Value (USD Billion)
9.2. Market Share & Forecast, 2017-2030
9.2.1. By Workflow
9.2.1.1. Discovery
9.2.1.1.1. Target Identification
9.2.1.1.2. Target Validation
9.2.1.1.3. Lead Discovery
9.2.1.2. Pre-Clinical Tests
9.2.1.3. Clinical Trials
9.2.2. By Product
9.2.2.1. Software
9.2.2.2. Services
9.2.3. By Software Type
9.2.3.1. Molecular Modeling Drug Design Software
9.2.3.2. Pharmacophore Modeling Software
9.2.4. By End-User
9.2.4.1. Contract Research Organizations
9.2.4.2. Pharmaceutical Industry
9.2.4.3. Academic and Research Institutes
9.2.4.4. Others (Hospitals and Other Care Facilities)
9.2.5. By Country
9.2.5.1. Brazil
9.2.5.2. Argentina
9.2.5.3. Rest of South America
9.2.6. Company Market Share (Top 3-5)
9.2.7. Economic Impact Study on South America In-Silico Drug Discovery Market
- The Middle East & Africa In-Silico Drug Discovery Market Overview
10.1. The Middle East & Africa In-Silico Drug Discovery Market Size & Forecast,2017-2030
10.1.1. Demand
10.1.1.1. By Value (USD Billion)
10.2. Market Share & Forecast, 2017-2030
10.2.1. By Workflow
10.2.1.1. Discovery
10.2.1.1.1. Target Identification
10.2.1.1.2. Target Validation
10.2.1.1.3. Lead Discovery
10.2.1.2. Pre-Clinical Tests
10.2.1.3. Clinical Trials
10.2.2. By Product
10.2.2.1. Software
10.2.2.2. Services
10.2.3. By Software Type
10.2.3.1. Molecular Modeling Drug Design Software
10.2.3.2. Pharmacophore Modeling Software
10.2.4. By End-User
10.2.4.1. Contract Research Organizations
10.2.4.2. Pharmaceutical Industry
10.2.4.3. Academic and Research Institutes
10.2.4.4. Others (Hospitals and Other Care Facilities)
10.2.5. By Country
10.2.5.1. Saudi Arabia
10.2.5.2. UAE
10.2.5.3. South Africa
10.2.5.4. Rest of the Middle East & Africa
10.2.6. Company Market Share (Top 3-5)
10.2.7. Economic Impact Study on Middle East & Africa In-Silico Drug Discovery Market
- Competitor Analysis
11.1. Company Description
11.2. Financial Analysis
11.3. Key Products
11.4. Key Management Personnel
11.5. Contact Address
11.6. SWOT Analysis
11.7. Company Profile
11.7.1. Albany Molecular Research Inc.
11.7.2. Certara USA, Inc.
11.7.3. Charles River
11.7.4. Chemical Computing Group
11.7.5. Collaborative Drug Discovery Inc.
11.7.6. Dassault System
11.7.7. Evotec A.G.
11.7.8. GVK Biosciences Private Limited
11.7.9. ICAGEN, INC.
11.7.10. Novo Informatics Pvt. Ltd.
11.7.11. Numerate Inc.
11.7.12. PerkinElmer Inc
11.7.13. Schrödinger, LLC
11.7.14. Selvita
11.7.15. Simulation Plus
11.7.16. WuXi AppTec
11.7.17. Other Prominent Players
Frequently Asked Questions (FAQ)
Global In-Silico Drug Discovery Market is estimated to reach USD 5.3 billion by 2030, growing at a CAGR of 7.4% during the forecast period of 2022-2030. It was valued at USD 2.8 billion in 2022.
The growth in the biomarker identification market and advancements in the field of computational biology would propel the growth of the global in-silico drug discovery market size in the forthcoming periods.
Companies such as Albany Molecular Research Inc., Certara USA, Inc., Charles River, Chemical Computing Group, Collaborative Drug Discovery Inc., Dassault System (Biovia), Evotec A.G., GVK Biosciences Private Limited, ICAGEN, INC. , Novo Informatics Pvt. Ltd., Numerate Inc., PerkinElmer Inc, Schrödinger, LLC, Selvita, Simulation Plus, and WuXi AppTec are the key players in the Global In-Silico Drug Discovery Market.
North America estimated to occupy the lion’s share in the in-silico drug discovery market.
